Ajinomoto Co., Inc. Enters Licensing Agreement with Astellas Pharma Inc. for Biopharmaceutical Development and Manufacturing Technology
Contributing to the Innovation and Enhanced Quality of Biopharmaceuticals Through AJICAP® Antibody-Drug Conjugate Technology TOKYO, October 31, 2025 – Ajinomoto Co., Inc. (“Ajinomoto Co.”) has signed a licensing agreement with Astellas Pharma Inc.…
